Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — FY2024 Earnings Presentation
11 slides from Aquestive Therapeutics's earnings presentation, Mar 5, 2025
Slide 1: Fourth Quarter and Full Year 2024 Earnings Supplemental Materials
Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Fourth Quarter and Full Year 2024 Earnings Supplemental Materials March 5, 2025
Slide 2: Disclaimer
© 2025 Aquestive Therapeutics, Inc. 2 ® Disclaimer Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” o
Slide 3: Q4/FY 2024 earnings key messages
3 Q4/FY 2024 earnings key messages Anaphylm (epinephrine) Sublingual Film for severe allergic reactions, including anaphylaxis • Positive topline results from OASIS study received in October 2024 • Successful Pre-NDA meeting in November 2024 • Initial pediatric clinical trial results in subjects 7-1
Slide 4: Upcoming expected key milestones
4 Upcoming expected key milestones AQST – 108 Libervant® Q1 2025 Q2 2025 Q3 2025 Q4 2025 Phase 2a Study Initiation AnaphlymTM NDA Submission Expected Pediatric Study Completion Open IND Expected NDA Acceptance Potential Advisory Committee Meeting Phase 2a Topline Readout Potential ex-US Approval Fil
Slide 5: Anaphylm Awareness, Trial, and Usage (ATU) findings
5 Anaphylm Awareness, Trial, and Usage (ATU) findings¹ 0% 20% 40% 60% 80% 100% Physicians NP/PA What % of time should patients carry their rescue medication? 0% 20% 40% 60% 80% 100% One Two More than Two How many rescue medications should be carried? 0% 20% 40% 60% 80% 100% Moderate to High Need (5-
Slide 6: AQST-108 planned Phase 2a clinical study for alopecia areata
6 AQST-108 planned Phase 2a clinical study for alopecia areata¹ 1. Plan on commencing study after alignment with the FDA. Phase 2a Study Design • 36 subjects, 3 doses • 12 – 24 weeks² • Early Responder Rate (ERR) of 10% (early responder defined as a subject with 20% improvement in SALT from baseline
Slide 7: Libervant for patients aged two to five continues to grow
7 Libervant for patients aged two to five continues to grow¹ 1. Aquestive Therapeutics, Inc. Data on File. ● Salesforce gaining traction with targeted HCPs ● Payor coverage continues to expand ● Medicaid reimbursable in all states with clinically appropriate edits (e.g., age) ● Negotiations complete
Slide 8: Positioned to meet near term milestones with projected cash runway into 2026
8 Positioned to meet near term milestones with projected cash runway into 2026 95.2 89.9 77.9 93 0 20 40 60 80 100 120 Q1 24 Q2 24 Q3 24 Q4 24 U S D ( M ill io n s ) Ending Cash Balance by Quarter 1. As of December 31, 2024, cash and cash equivalents was $71.5 million. Proforma cash which includes c
Slide 9: Doses Shipped by Quarter
9 47,041 41,097 36,863 33,458 47,953 46,241 45,328 42,516 34,418 43,818 43,032 0 10,000 20,000 30,000 40,000 50,000 60,000 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 D O S E S S H IP P E D ( 0 0 0 ’S ) QUARTER Doses Shipped by Quarter Manufacturing operations continue to gener
Slide 10: Full year 2024 results and 2025 guidance
10 Full year 2024 results and 2025 guidance 2024 Results • Revenue of $57.6 million • Non-GAAP adjusted EBITDA loss was $23 million 2025 Outlook • Total revenues of approximately $47-$56 million • Non-GAAP adjusted EBITDA loss of approximately $46-$53 million¹ 1. Increase to year over year loss prim
Slide 11: Thank You
<< Aquestive’ Thank You
Aquestive Therapeutics — FY2024 Earnings Presentation on 6ix